Mechanisms of stem cell effects: Insights from MRI

Minerva Cardioangiologica

Volumn 61, Issue 6, 2013, Pages 605-616

  Rokosh, G ^a   Ghafghazi, S ^a   Bolli, R ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Magnetic resonance imaging; Myocardial infarction; Regeneration; Stem cells

Indexed keywords

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCARDIUM; RECOVERY OF FUNCTION; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; VENTRICULAR REMODELING;

EID: 84894252227     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Orlic D, Kajstura J, Chimenti S., Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 2001; 938: 221-229; discussion 229-30
2. Orlic D, Kajstura J, Chimenti S., Jakoniuk I, Anderson SM, Li B, Pickel J., McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
3. Orlic D, Kajstura J, Chimenti S., Limana F, Jakoniuk I, Quaini F et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98: 10344-9.
4. Jeevanantham V, Butler M, Saad A., Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis. Circulation 2012; 126: 551-68.
5. Leistner DM, Zeiher AM. Novel avenues for cell therapy in acute myocardial infarction. Circ Res 2012; 110: 195-7.
6. Hare JM, Fishman JE, Gerstenblith G, Di Fede Velazquez DL, Zambrano JP et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA 2012; 308: 2369-79.
7. Penn MS, Ellis S, Gandhi S., Greenbaum A, Hodes Z, Mendelsohn FO et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase i clinical study. Circ Res 2012; 110: 304-11.
8. Marban E, Malliaras K. Mixed results for bone marrow-derived cell therapy for ischemic heart disease. JAMA 2012; 308: 2405-6.
9. Sheridan C. Cardiac stem cell therapies inch toward clinical litmus test. Nature Biotechnol 2013: 31: 5-6.
10. Beltrami AP, Barlucchi L, Torella D., Baker M, Limana F, Chimenti S et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-76.
11. Urbanek K, Cesselli D, Rota M., Nascimbene A, De Angelis A, Hosoda T et al. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci U S A 2006; 103. 9226-31.
12. Dawn B, Guo Y, Rezazadeh A., Huang Y, Stein AB, Hunt G et al Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 2006, 98: 1098-105.
13. Dawn B, Stein AB, Urbanek K, Rota M., Whang B, Rastaldo R et al. Cardiac stem cells delivered intra-vascularly traverse the vessel barrier, regenerate in-farcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A 2005; 102: 3766-71.
14. Dawn B, Tiwari S, Kucia M.J., Zuba-Surma EK, Guo Y, Sanganalmath SK et al. Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction. Stem Cells 2008; 26: 1646-55.
15. Kucia M, Dawn B, Hunt G., Guo Y, Wysoczynski M, Majka M et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004; 95: 1191-9.
16. Sekiguchi H, Ii M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol 2009; 219: 235-42.
17. Linke A, Muller P, Nurzynska D., Casarsa C, Torella D, Nascimbene A et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A 2005; 102: 8966-71.
18. Rota M, Padin-Iruegas ME, Misao Y., De Angelis A, Maestroni S, Ferreira-Martins J et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac fonction. Circ Res 2008; 103: 107-16.
19. Balsam LB, Wagers AJ, Christensen J.L., Kofidis T., Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428: 668-73.
20. Murry CE, Soonpaa MH, Reinecke H, Nakajima H., Nakajima HO, Rubart M et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-8.
21. Gnecchi M, He H, Noiseux N., Liang OD, Zhang L, Morello F et al. Evidence supporting paracrine hypothesis for akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J 2006; 20: 661-9.
22. Mangi AA, Noiseux N, Kong D., He H, Rezvani M, Ingwall JS et al. Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts. Nature medicine 2003; 9: 1195-201.
23. Tang XL, Rokosh G, Sanganalmath S., Yuan F, Sato H, Mu J et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day old infarction. Circulation 2010; 121: 293-305.
24. Wang WE, Yang D, Li L., Wang W, Peng Y, Chen C et al. Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. Circ Res 2013; 113: 288-300.
25. Burt RK, Chen YH, Verda L, Lucena C., Navale S, Johnson J et al. Mitotically inactivated embryonic stem cells can be used as an in vivo feeder layer to nurse damaged myocardium after acute myocardial infarction: A preclinical study. Circ Res 2012; 111: 1286-1296
26. Liu J, Narsinh KH, Lan F, Wang L., Nguyen PK, Hu S, Lee A, Han L., Gong Y, Huang M, Nag D., Rosenberg J, Chouldechova A, Robbins R.C., Wu JC. Early stem cell engraftment predicts late cardiac functional recovery: Preclinical insights from molecular imaging. Circulation. Cardiovasc Imaging 2012; 5: 481-90.
27. Chen IY, Wu JC. Molecular imaging: the key to advancing cardiac stem cell therapy. Trends Cardiovasc Med 2013; 23: 201-10.
28. Flett AS, Hasleton J, Cook C., Hausenloy D, Quarta G, Ariti C et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging 2011; 4: 150-6.
29. Hsu LY, Ingkanisorn WP, Keilman P, Aletras A.H., Arai AE. Quantitative myocardial infarction on delayed enhancement MRI. Part II: Clinical application of an automated feature analysis and combined thresholding infarct sizing algorithm. J Magn Reson Imaging 2006; 23: 309-14.
30. Hsu LY, Natanzon A, Keilman P., Hirsch GA, Aletras AH, Arai AE. Quantitative myocardial infarction on delayed enhancement MRI. Part I: Animal validation of an automated feature analysis and combined thresholding infarct sizing algorithm. J Magn Reson Imaging 2006; 23: 298-308.
31. Nacif MS, Chugh AR, Lima J.A., Bluemke DA. How should infarct size be measured on LGE sequences? A call for a change in the guidelines. JACC Cardiovasc Imaging 2011; 4: 1223; author reply 4.
32. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med 2006; 3: 554-62.
33. Mathiasen AB, Hansen L, Friis T., Thomsen C, Bhakoo K, Kastrup J. Optimal labeling dose, labeling time, and magnetic resonance imaging detection limits of ultrasmall superparamagnetic iron-oxide nanoparti-cle labeled mesenchymal stromal cells. Stem Cells Int 2013; 2013: 353105.
34. Budde MD, Frank JA. Magnetic tagging of therapeutic cells for MRI. J Nucl Med 2009; 50: 171-4.
35. Pawelczyk E, Arbab AS, Chaudhry A, Balakumaran A., Robey PG, Frank JA. In vitro model of bromodeoxyu-ridine or iron oxide nanoparticle uptake by activated macrophages from labeled stem cells: implications for cellular therapy. Stem Cells 2008; 26: 1366-75.
36. Beeres SL, Bengel FM, Bartunek J, Atsma D.E., Hill JM, Vanderheyden M et al. Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol 2007; 49: 1137-48.
37. Shapiro EM, Sharer K, Skrtic S., Koretsky AP. In vivo detection of single cells by MRI. Contrast Media Mol Imaging 2006; 55: 242-9.
38. Heyn C, Ronald JA, Ramadan S.S., Snir JA, Barry AM, MacKenzie LT et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med 2006, 56: 1001-10.
39. Chen IY, Grève JM, Gheysens O., Willmann JK, Rodriguez-Porcel M, Chu P et al. Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol Imaging Biol 2009; 11: 178-87.
40. Cao J, Wang YN, Shi X.L., Ma GT, Kong LY, Xue HD et al. In vivo and in vitro imaging tracing of dual-labeled bone mesenchymal stem cells transplanted into myocardium of F344 rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2012; 34: 474-9.
41. Campan M, Lionetti V, Aquaro G.D., Forini F., Matteucci M, Vannucci L et al. Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiac MRI in a rat model of myocardial infarction. Am J Physiol Heart Circul Physiol 2011; 300: H2238-50.
42. Hendel RC, Patel MR, Kramer C.M., Poon M., Hendel RC, Carr JC et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 2006; 48: 1475-97.
43. Kim RJ, Wu E, Rafael A., Chen EL, Parker MA, Simonetti O et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. New Engl J Med 2000; 343: 1445-53.
44. Soliman OI, Kirschbaum SW, van Dalen BM, van der Zwaan HB, Mahdavian Delavary B, Vletter WB et al. Accuracy and reproducibility of quantitation of left ventricular function by real-time three-dimensional echocardiography versus cardiac magnetic resonance. Am J Cardiol 2008; 102: 778-83.
45. Petersen JW, Forder JR, Thomas J.D., Moye LA, Lawson M, Loghin C et al. Quantification of myocardial segmental function in acute and chronic ischemic heart disease and implications for cardiovascular cell therapy trials: a review from the NHLBI-Cardiovascular Cell Therapy Research Network. JACC Cardiovasc Imaging 2011; 4: 671-9.
46. Wollert KC, Meyer GP, Lotz J, Ringes Lichtenberg S, Lippolt P, Breidenbach C et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-8.
47. Assmus B, Schachinger V, Teupe C., Britten M, Lehmann R, Dobert N et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17.
48. Britten MB, Abolmaali ND, Assmus B, Lehmann R., Honold J, Schmitt J et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003; 108: 2212-8.
49. Janssens S, Dubois C, Bogaert J., Theunissen K, Deroose C, Desmet W et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-seg-ment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113-21.
50. Lunde K, Solheim S, Aakhus S., Arnesen H, Abdelnoor M, Egeland T et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. New Engl J Med 2006; 355: 1199-209.
51. Schachinger V, Erbs S, Elsasser A., Haberbosch W, Hambrecht R, Holschermann H et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. New En
52. Dill T, Schachinger V, Rolf A, Mollmann S, Thiele H, Tillmanns H et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009; 157: 541-7.
53. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard M.F., Ikram S et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378: 1847-57.
54. Hopp E, Lunde K, Solheim S., Aakhus S, Arnesen H, Forfang K et al. Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study. J Cardiovasc Magn Reson 2011; 13: 22.
55. Traverse JH, Henry TD, Ellis S.G., Pepine CJ, Willerson JT, Zhao DX et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: The latetime randomized trial. JAMA 2011; 306: 2110-9.
56. Makkar RR, Smith RR, Cheng K, Malliaras K., Thomson LE, Berman D et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
57. Traverse JH, Henry TD, Pepine C.J., Willerson JT, Zhao DX, Ellis SG et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The time randomized trial. JAMA 2012; 308: 2380-9.
58. Schachinger V, Assmus B, Britten M.B., Honold J., Lehmann R, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-9.
59. Kang HJ, Lee HY, Na S.H., Chang SA, Park KW, Kim HK et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006; 114(1 Suppl): 1145-51.
60. Surder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K., Soncin S et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 2013; 127: 1968-79.
61. Fuster V, Sanz J, Viles-Gonzalez JF, Rajagopalan S. The utility of magnetic resonance imaging in cardiac tissue regeneration trials. Nat Clin Pract Cardiovasc Med 2006; 3 Suppl 1: S2-7.
62. Solomon SD, Anavekar N, Skali H., McMurray JJ, Swedberg K, Yusuf S et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738-44.
63. Herbots L, D'Hooge J, Eroglu E, Thijs D., Ganame J, Claus P et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study. Eur Heart J 2009; 30: 662-70.
64. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging 2009; 2: 356-64.
65. Reffelmann T, Konemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 2009; 53: 305-8.
66. Clifford DM, Fisher SA, Brunskill S.J., Doree C., Mathur A, Watt S et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Systematic Rev 2012; 2: Cd006536.
67. Kandala J, Upadhyay GA, Pokushalov E, Wu S., Drachman DE, Singh JP. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 2013; 112: 217-25.
68. Fernandez-Armenta J., Berruezo A, Mont L., Sitges M, Andreu D, Silva E et al. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace 2012; 14: 1578-86.
69. Kwong RY, Chan AK, Brown K.A., Chan CW, Reynolds HG, Tsang S et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113-2733-43.
70. Gerber BL, Rousseau MF, Ahn S.A., le Polain de Waroux JB, Pouleur AC, Phlips T et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol 2012; 59: 825-35.
71. Kwon DH, Hachamovitch R, Popovic Z.B., Starling RC, Desai MY, Flamm SD et al. Survival in patients with severe ischemic cardiomyopathy undergoing revascularization versus medical therapy: association with end-systolic volume and viability. Circulation 2012; 126(11 Suppl 1): S3-8.
72. Neilan TG, Coelho-Filho OR, Danik S.B., Shah RV, Dodson JA, Verdini DJ et al. CMR Quantification of Myocardial Scar Provides Additive Prognostic Information in Nonischemic Cardiomyopathy. JACC Cardiovasc Imaging 2013; 6: 944-54.
73. Assmus B, Rolf A, Erbs S., Elsasser A, Haberbosch W, Hambrecht R et al. Clinical outcome 2 years after in-tracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circulation Heart Failure 2010; 3: 89-96.
74. Hundley WG, Bluemke D, Bogaert J.G., Friedrich MG, Higgins CB, Lawson MA et al. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 2009; 11: 5.
75. Vermes E, Childs H, Carbone I., Barckow P, Friedrich MG. Auto-threshold quantification of late gadolinium enhancement in patients with acute heart disease. J Magn Reson Imaging 2013; 37: 382-90.
76. Leistner DM, Fischer-Rasokat U, Honold J., Seeger FH, Schachinger V, Lehmann R et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011; 100: 925-34.
77. Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J 2011; 32: 1736-47.
78. Klug G, Mayr A, Schenk S., Esterhammer R, Schocke M, Nocker M et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. JJ Cardiovasc Magn Reson 2012; 14: 46.
79. Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet N.R., Cademartiri F et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. J Am Coll Cardiol 2006; 47: 40-4.
80. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010; 55: 1649-60.
81. Roncalli J, Mouquet F, Piot C., Trochu JN, Le Corvoisier P, Neuder Y et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32: 1748-57.
82. Zimmet H, Porapakkham P, Porapakkham P., Sata Y, Haas SJ, Itescu S et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail 2012; 14: 91-105.
83. Wöhrle J., Merkle N, Mailänder V, Nusser T., Schauwecker P, von Scheidt F et al. Results of Intracoronary Stem Cell Therapy After Acute Myocardial Infarction. Am J Cardiol 2010; 105: 804-12.
84. Perin EC, Willerson JT, Pepine C.J., Henry TD, Ellis SG, Zhao DX et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012; 307: 1717-26.
85. Meyer GP, Wollen KC, Lotz J, Pirr J., Rager U, Lippolt P et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009; 30: 2978-84.
86. Tendera M, Wojakowski W, Ruzyllo W., Chojnowska L, Kepka C, Tracz W et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009; 30: 1313-21.
87. Perm MS. Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk. Lancet 2006; 367: 87-8.
88. Perin EC, Dohmann HF, Borojevic R, Silva S.A., Sousa AL, Mesquita CT et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-302.
89. Patel AN, Geffner L, Vina R.F., Saslavsky J., Urschel HC Jr., Kormos R et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 2005; 130: 1631-8.
90. Hendriks M, Hensen K, Clijsters C., Jongen H, Koninckx R, Bijnens E et al. Recovery of regional but not global contractile function by the direct intramyocar-dial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006; 114(1 Suppl): I101-7.
91. Stamm C, Kleine HD, Choi Y.H., Dunkelmann S., Lauffs JA, Lorenzen B et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 2007; 133: 717-25.
92. Zhao Q, Sun Y, Xia L., Chen A, Wang Z. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 2008; 86: 1833-40.
93. Pokushalov E, Romanov A, Chernyavsky A., Larionov P, Terekhov I, Artyomenko S et al. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure, a randomized study. J Cardiovasc Transi Res 2010; 3: 160-8.
94. Hu S, Liu S, Zheng Z., Yuan X, Li L, Lu M et al. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2011; 57: 2409-15.
95. Williams AR, Trachtenberg B, Velazquez D.L., McNiece I., Altman P, Rouy D et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011; 108: 792-6.
96. Chugh AR, Beache GM, Loughran J.H., Mewton N., Elmore JB, Kajstura J et al. Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SC1PIO Trial: Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance. Circulation 2012; 126(11 Suppl 1): S54-64.
97. Assmus B, Walter DH, Seeger F.H., Leistner DM, Steiner J, Ziegler I et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013; 309: 1622-31.
98. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell stem cell 2011; 8(4): 389-98.
99. Senyo SE, Steinhauser ML, Pizzimenti C.L., Yang VK, Cai L, Wang M et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 2013; 493: 433-6.